Logo image of PCRX

PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis

NASDAQ:PCRX - Nasdaq - US6951271005 - Common Stock - Currency: USD

26.54  -0.21 (-0.79%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to PCRX. PCRX was compared to 198 industry peers in the Pharmaceuticals industry. PCRX scores excellent on profitability, but there are some minor concerns on its financial health. PCRX scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make PCRX a good candidate for value investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year PCRX was profitable.
In the past year PCRX had a positive cash flow from operations.
PCRX had positive earnings in 4 of the past 5 years.
In the past 5 years PCRX always reported a positive cash flow from operatings.
PCRX Yearly Net Income VS EBIT VS OCF VS FCFPCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

Looking at the Return On Assets, with a value of -5.97%, PCRX is in the better half of the industry, outperforming 72.22% of the companies in the same industry.
With a decent Return On Equity value of -11.87%, PCRX is doing good in the industry, outperforming 76.77% of the companies in the same industry.
PCRX has a better Return On Invested Capital (5.65%) than 83.33% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 42.34%.
The 3 year average ROIC (4.17%) for PCRX is below the current ROIC(5.65%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -5.97%
ROE -11.87%
ROIC 5.65%
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
PCRX Yearly ROA, ROE, ROICPCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

The Operating Margin of PCRX (12.16%) is better than 82.83% of its industry peers.
PCRX's Operating Margin has improved in the last couple of years.
PCRX has a Gross Margin of 76.46%. This is amongst the best in the industry. PCRX outperforms 83.84% of its industry peers.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
Industry RankSector Rank
OM 12.16%
PM (TTM) N/A
GM 76.46%
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
PCRX Yearly Profit, Operating, Gross MarginsPCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
PCRX has less shares outstanding than it did 1 year ago.
PCRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PCRX has a worse debt to assets ratio.
PCRX Yearly Shares OutstandingPCRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PCRX Yearly Total Debt VS Total AssetsPCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 1.87 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
PCRX has a Altman-Z score of 1.87. This is in the better half of the industry: PCRX outperforms 68.69% of its industry peers.
PCRX has a debt to FCF ratio of 3.66. This is a good value and a sign of high solvency as PCRX would need 3.66 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.66, PCRX belongs to the top of the industry, outperforming 87.88% of the companies in the same industry.
A Debt/Equity ratio of 0.48 indicates that PCRX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.48, PCRX is not doing good in the industry: 60.10% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.66
Altman-Z 1.87
ROIC/WACC0.66
WACC8.52%
PCRX Yearly LT Debt VS Equity VS FCFPCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

PCRX has a Current Ratio of 2.41. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
PCRX has a Current ratio (2.41) which is comparable to the rest of the industry.
A Quick Ratio of 1.99 indicates that PCRX should not have too much problems paying its short term obligations.
PCRX's Quick ratio of 1.99 is in line compared to the rest of the industry. PCRX outperforms 46.46% of its industry peers.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 1.99
PCRX Yearly Current Assets VS Current LiabilitesPCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.64% over the past year.
The Earnings Per Share has been growing by 13.96% on average over the past years. This is quite good.
Looking at the last year, PCRX shows a very strong growth in Revenue. The Revenue has grown by 27.59%.
PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.73% yearly.
EPS 1Y (TTM)6.64%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%0%
Revenue 1Y (TTM)27.59%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.08%

3.2 Future

The Earnings Per Share is expected to grow by 13.49% on average over the next years. This is quite good.
Based on estimates for the next years, PCRX will show a quite strong growth in Revenue. The Revenue will grow by 9.51% on average per year.
EPS Next Y-10.41%
EPS Next 2Y5.26%
EPS Next 3Y11.63%
EPS Next 5Y13.49%
Revenue Next Year6.71%
Revenue Next 2Y9.15%
Revenue Next 3Y9.46%
Revenue Next 5Y9.51%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PCRX Yearly Revenue VS EstimatesPCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
PCRX Yearly EPS VS EstimatesPCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

PCRX is valuated reasonably with a Price/Earnings ratio of 8.27.
Based on the Price/Earnings ratio, PCRX is valued cheaper than 92.42% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.60, PCRX is valued rather cheaply.
PCRX is valuated cheaply with a Price/Forward Earnings ratio of 7.46.
Based on the Price/Forward Earnings ratio, PCRX is valued cheaper than 91.41% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.43, PCRX is valued rather cheaply.
Industry RankSector Rank
PE 8.27
Fwd PE 7.46
PCRX Price Earnings VS Forward Price EarningsPCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaply inside the industry as 92.93% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 93.94% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 7.71
EV/EBITDA 5.97
PCRX Per share dataPCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.59
EPS Next 2Y5.26%
EPS Next 3Y11.63%

More info and screens

0

5. Dividend

5.1 Amount

PCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (5/21/2025, 12:56:54 PM)

26.54

-0.21 (-0.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)07-28 2025-07-28/amc
Inst Owners112.14%
Inst Owner Change1.55%
Ins Owners2.41%
Ins Owner Change32.53%
Market Cap1.23B
Analysts75.38
Price Target39.78 (49.89%)
Short Float %13.52%
Short Ratio6.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.4%
Min EPS beat(2)1.99%
Max EPS beat(2)6.81%
EPS beat(4)4
Avg EPS beat(4)10.88%
Min EPS beat(4)1.99%
Max EPS beat(4)24.81%
EPS beat(8)5
Avg EPS beat(8)3.83%
EPS beat(12)5
Avg EPS beat(12)-4.15%
EPS beat(16)8
Avg EPS beat(16)-3.65%
Revenue beat(2)0
Avg Revenue beat(2)-3.17%
Min Revenue beat(2)-5.92%
Max Revenue beat(2)-0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.94%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)1.18%
Revenue beat(8)1
Avg Revenue beat(8)-2.72%
Revenue beat(12)1
Avg Revenue beat(12)-2.57%
Revenue beat(16)2
Avg Revenue beat(16)-2.32%
PT rev (1m)14.04%
PT rev (3m)57.8%
EPS NQ rev (1m)-5.13%
EPS NQ rev (3m)-22.84%
EPS NY rev (1m)-2.81%
EPS NY rev (3m)-18.1%
Revenue NQ rev (1m)-1.14%
Revenue NQ rev (3m)-2.52%
Revenue NY rev (1m)-0.78%
Revenue NY rev (3m)1.18%
Valuation
Industry RankSector Rank
PE 8.27
Fwd PE 7.46
P/S 1.41
P/FCF 7.71
P/OCF 6.99
P/B 1.54
P/tB 3.59
EV/EBITDA 5.97
EPS(TTM)3.21
EY12.09%
EPS(NY)3.56
Fwd EY13.4%
FCF(TTM)3.44
FCFY12.97%
OCF(TTM)3.8
OCFY14.31%
SpS18.79
BVpS17.25
TBVpS7.39
PEG (NY)N/A
PEG (5Y)0.59
Profitability
Industry RankSector Rank
ROA -5.97%
ROE -11.87%
ROCE 8.31%
ROIC 5.65%
ROICexc 9.24%
ROICexgc 22.34%
OM 12.16%
PM (TTM) N/A
GM 76.46%
FCFM 18.32%
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
ROICexc(3y)5.86%
ROICexc(5y)7.17%
ROICexgc(3y)13.2%
ROICexgc(5y)24.66%
ROCE(3y)6.13%
ROCE(5y)6.57%
ROICexcg growth 3Y-34.27%
ROICexcg growth 5Y13.31%
ROICexc growth 3Y-4.56%
ROICexc growth 5Y9.22%
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.66
Debt/EBITDA 2.04
Cap/Depr 20.05%
Cap/Sales 1.88%
Interest Coverage 7.47
Cash Conversion 93.84%
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 1.99
Altman-Z 1.87
F-Score5
WACC8.52%
ROIC/WACC0.66
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.64%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%0%
EPS Next Y-10.41%
EPS Next 2Y5.26%
EPS Next 3Y11.63%
EPS Next 5Y13.49%
Revenue 1Y (TTM)27.59%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.08%
Revenue Next Year6.71%
Revenue Next 2Y9.15%
Revenue Next 3Y9.46%
Revenue Next 5Y9.51%
EBIT growth 1Y13.13%
EBIT growth 3Y-9.76%
EBIT growth 5Y22.27%
EBIT Next Year4.65%
EBIT Next 3Y15%
EBIT Next 5Y20.69%
FCF growth 1Y52.39%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y31.55%
OCF growth 3Y14.64%
OCF growth 5Y21.85%